Milestone Payment for Supernus - Analyst Blog

By
A A A

Several pharma/biotech companies collaborate for the development and commercialization of products. These collaborations make sense as they allow the companies to bring together their expertise, technical knowhow and resources. Where financial terms are concerned, these agreements are typically structured to include an upfront payment and additional payments on the achievement of milestones besides royalties.

Earlier this week, Supernus Pharmaceuticals, Inc. ( SUPN ) announced that it has received a milestone payment of $2 million from partner United Therapeutics Corp. ( UTHR ) for the launch of Orenitram (treprostinil) extended-release tablets. Supernus will also receive royalties on net sales of Orenitram and additional payments on the achievement of certain milestones.

We note that Orenitram was developed by United Therapeutics using Supernus' patented technology platform. It was approved in Dec 2013 for the treatment of pulmonary arterial hypertension (PAH) patients (in World Health Organization (WHO) Group I) for improving their exercise capacity. The product was launched in Apr 2014.

We note that subcutaneous and intravenous formulations of Orenitram are already available under the trade name Remodulin for the treatment of PAH.

Orenitram has orphan drug status in the EU for the treatment of PAH. An application for orphan drug designation for Orenitram is under the U.S. Food and Drug Administration's (FDA) review.

The milestone payment of $2 million received by Supernus will add to the company's topline. In 2014, Supernus expects revenues in the range of $75 million−$85 million. The Zacks Consensus Estimate for revenues of $80 million is within this guidance range.

Supernus carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Mallinckrodt plc ( MNK ) and Akorn, Inc. ( AKRX ). While Mallinckrodt carries a Zacks Rank #1 (Strong Buy), Akorn holds a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AKORN INC (AKRX): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

SUPERNUS PHARMA (SUPN): Free Stock Analysis Report

UTD THERAPEUTIC (UTHR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: PAH , AKRX , MNK , SUPN , UTHR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Can Magnets Relieve Pain?
Can Magnets Relieve Pain?           
The Danger of Small ETFs
The Danger of Small ETFs            

Stocks

Referenced

Most Active by Volume

34,244,070
  • $16.225 ▼ 0.64%
29,039,483
  • $102.16 ▲ 1.26%
26,454,027
  • $75.14 ▼ 1.08%
24,013,579
  • $3.585 ▲ 0.70%
21,369,537
  • $19.215 ▲ 5.40%
18,767,303
  • $48.121 ▼ 0.10%
16,478,373
  • $38.275 ▲ 1.28%
15,115,578
  • $11.14 ▲ 3.15%
As of 8/27/2014, 02:00 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com